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Transposons are an attractive system to use in genetic screens as they are molecularly tractable and the
disrupted loci that give rise to the desired phenotype are easily mapped. We consider herein the charac-
teristics of the piggyBac transposon system in complementing existing mammalian screen strategies,
including the Sleeping Beauty transposon system. We also describe the design of the piggyBac resources
that we have developed for both forward and reverse genetic screens, and the protocols we use in these
experiments.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction
Genetic screens in model organisms represent a stalwart means
of gene function discovery. Class II transposable elements or DNA
transposons are mobile elements that can relocate between geno-
mic loci via a ‘cut and paste’ mechanism, they are proven work-
horses in the molecular toolkit of diverse genetic models from
the fruitﬂy to maize [1,2]. DNA transposons comprise two principle
components, the transposase enzyme that mediates the transposi-
tion process itself and the inverted terminal repeats ﬂanking the
transposition cargo that the transposase recognises. This relocation
activity of DNA transposons has been exploited to great effect in
Drosophila for diverse purposes, ranging from transgene delivery
to mutagenesis to chromosome engineering [3].
Two transposition systems developed for use in mammalian
systems have come to the fore in recent years – Sleeping Beauty
(SB) and piggyBac (PB). Sleeping Beauty (SB) was engineered from
Tc1/mariner transposon fossils in salmonid ﬁsh genomes by com-
parative phylogenetic analysis [4]. More recently, piggyBac (PB),
which was originally characterised in insects, was found to trans-
pose efﬁciently in the mammalian cells [5–7].
1.1. piggyBac traits and considerations in experiments
PB transposase recognises a short TTAAmotif in the host genome
for insertion and excises the transposon without mutation [6,8]. In
mammalian cells, due to the different transposition characteristics
of Sleeping Beauty and piggyBac, it can be advantageous to use both
systems together in some cases. We describe herein the design license.and methodologies of both forward and reverse genetic screens
using different PB constructswehave developed (Fig. 1).Whilemost
of the considerations in the experimental designs make use of the
traits unique to PB, these constructs have nested SB terminal repeats
to yield maximal ﬂexibility in the experimental design.
We have previously described the direct co-electroporation of a
plasmid containing the PB transposase with a second plasmid con-
taining the PB transposon as an efﬁcient way of transducing mouse
embryonic stem (ES) cells 2–3 orders of magnitude higher than
SB11, with approximately 28% of cells that survive electroporation
transduced [7]. Transposase is transiently expressed from the
‘helper’ plasmid, excising the transposon from the ‘donor’ plasmid
and integrating it randomly into the genome. Depending on the
experimental design, we also previously described the construc-
tion of mPB-L3-ERT2, which is a constitutively expressed transpos-
ase that is inactive until the addition of its chemical inducer
4-hydroxytamoxifen (4-OHT) [5]. This gives further ﬂexibility in
the control of transposition. In comparison, standard techniques
for transgenics such as knock-in gene targeting are useful where
a single copy of transposon and deﬁned locus is required. Pro-nu-
clear injection will generate concatemers at random insertion sites
and also result in transgenic lines with variable copy numbers, but
lack the ﬂexibility of being able to genotype and select for clones of
interest before establishing the animal line.
PB transposition is unaffected by cargo sizes up to 9.1 kb, show-
ing some reduction in efﬁciency at 14.3 kb [6]. Over-production
inhibition (OPI) is a phenomenon that affects most transposable
elements where increasing cellular transposase concentration be-
yond a certain threshold decreases transposition efﬁciency, though
different studies have described both the presence and lack of OPI
for PB [9,10]. Although we have not observed OPI in our experi-
ments, when working with a new cell line, it is advisable to try
Fig. 1. Catalogue of transposon designs useful for different genetic screens. They all have PB inverse terminal repeats to facilitate delivery and nested SB within it for
ﬂexibility in subsequent mobilisation (TR, terminal repeat; SA, splice acceptor; pA, polyadenylation sequence; SD, splice donor; IRES, internal ribosomal entry site).
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tions to assay efﬁciency. Since all that is needed for transposase
mediated integration of the transposon cargo into the genome is
the introduction of the two DNA plasmids into the cell, the actual
method of DNA delivery itself is quite ﬂexible. We routinely use
electroporation, transfection or nucleofection in both murine and
human cells, the selection of the delivery system is dependent on
the particular cell type in question.
Another consideration in utilising transposons is the presence
of local hopping. During transposition, DNA transposons often have
a propensity of reintegrating near the original excision site, a cer-
tain percentage of transposition events will be local and the rest
would usually be distributed evenly across the genome, subject
to other biases and tendencies. In mammalian cells, PB exhibits
approximately either low (approximately 10%) or no reported local
hopping (this is possibly context or loci dependent), and had a nar-
row local hopping distribution of approximately 100 kb from the
donor site [6,7,11]. The rest of the insertion events seem random
and evenly distributed across the genome. By comparison, SB is
reported to exhibit local hopping in the range of approximately
10–75% contingent on the tissue and cellular context, with a distri-
bution in the region of 3–6 mb from the donor site [12–15]. By
using either or both systems, a library of desired distribution and
saturation can be created. Chromosome engineering and screen
strategies that harness the local hopping traits of transposon have
been described in both insect and mammalian systems [16,17].1.2. Designing piggyBac genetic screens
For mammalian models, point mutagens such as N-ethyl-N-
nitrosourea (ENU) and insertional mutagenesis by viruses have
been used with great success in diverse applications, though there
were also inherent limitations. These range from the scale and costof recovering mutations (for ENU) to viral tropism and insertion
site biases within the genome.
The Sleeping Beauty transposon system has been used success-
fully for somatic insertional mutagenesis and cancer gene discov-
ery in multiple tissues [13,18,19]. We have found that the
piggyBac system is complementary to Sleeping Beauty in terms of
the novel cancer genes identiﬁed [20]. The design of the transposon
construct depends on the kind of genes to be identiﬁed from the
screen. We have constructed three designs of transposons for
insertional mutagenesis – bi-functional transposons that both
inactivate local transcripts and ectopically activate surrounding
genes, inactivating transposons that inactivate local transcripts,
and activating transposons to drive expression of nearby genes
(Fig. 1A–D). It is also possible to include a sensitising or coopera-
tive transgene within the transposon itself (Fig. 1D), this makes
use of the larger cargo capacity of the PB transposon and is not
dependent on the availability of an existing mutant mouse strain.
It allows both the delivery of sensitising mutations that are gain
of function from expression of a cDNA as well as knockdown of a
tumour suppressor gene using shRNAs. Multiple combinations of
sensitising alleles can be assembled by using T2A junctions be-
tween cDNAs, so that two or more cDNAs are expressed from the
promoter [21].
The considerations for choice of transposon design in a
cell-based phenotypic screen are similar. The expression of PB
transposase would usually be transient in such an experiment
(see Section 3.1), so the saturation and genome coverage of the
screen would be dependent on the number of cells bearing trans-
posons. The transduction efﬁciency when starting work on a new
cell line should be assayed using a selectable control transposon
such as PB-SB-PGK-Neo.
Given the ﬂexibility of transgene delivery for PB, it is easily
adapted for the construction of a cDNA expression library for
reverse genetic screens (Fig. 1E and F). We have cloned collections
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For cell-based experiments, an overexpression construct (Fig. 1E)
with a promoter such as CAGG (synthetic cytomegalovirus [CMV]
early enhancer and chicken b-actin promoter hybrid) or PGK
(phosphoglycerate kinase promoter) is used to deliver genes of
interest into cells. In addition to assaying a single gene/construct
per experiment, a library pool of transposons can be used in a sin-
gle electroporation, resulting in a heterogeneous mixture of cells.
Selecting for the phenotype of interest would then allow the recov-
ery of the transposon or combination of transposons responsible
for the cellular phenotype. We have also applied the pooled trans-
poson approach to validating cancer mutations identiﬁed in hu-
man cancer genomes. We cloned a collection of mutant cDNAs
into a promoter trap transposon (Fig. 1F) and generated animals
that stochastically express the mutant cDNAs in vivo. Oncogenic
mutant cDNAs transposons are recovered by analysing the trans-
posons that are expressed in tumours that arise in these animals.
Comprehensive cDNA and shRNA libraries constructed in the PB
transposon will enable prospective genetic screens.2. Materials
We have previously described both the PB transposase sources
and the original vector backbone of the PB–SB hybrid transposon
used to generate subsequent transposon constructs [5,7].
Published materials from us are available at http://www.sanger.
ac.uk/technology/clonerequests/.
2.1. Transposase source
1. CAGG-PBase plasmid construct – PL622 is a plasmid source of PB
transposase driven by the constitutive CAGG promoter (syn-
thetic cytomegalovirus [CMV] early enhancer and chicken b-
actin promoter hybrid).
2. Rosa-PBase knock-in mouse line – the knock-in Rosa-PBase allele
was targeted and characterised in AB2.2 mouse embryonic stem
(ES) cell line, and subsequently used to generate the PLPB
mouse line by blastocyst injection.
2.2. Plasmid constructs
Fig. 1 outlines a catalogue of transposon constructs for different
uses. We incorporate unique sequence tags in the 30 end of the
expression constructs to facilitate transgene tracking and differen-
tiation of the introduced cDNAs from an endogenous expression.
We have used both standard techniques and throughput scalable
In-fusion Advantage PCR cloning kit (Clontech 639620) to generate
constructs. Plasmid DNA is prepared using maxiprep plasmid puri-
ﬁcation kits (Qiagen 12163), resuspended at 1 lg/ml and stored at
20 C.
1. Bi-functional activating/inactivating (Fig. 1A) – this transposon
design causes loss of function to genes it lands in by either
direct insertional disruption of the coding sequence or by trap-
ping transcripts via the splice acceptors in both orientations. It
also mediates ectopic gain of function by directional activation
of nearby genes from the promoter and splice-donor.
2. Inactivating (Fig. 1B and C) – these transposons causes loss of
function to genes it lands in by either direct insertional disrup-
tion of the coding sequence or by trapping transcripts via the
splice acceptors in both orientations. The b-geo (b-galactosidase
and neomycin phosphotransferase fusion) cassette provides a
reporter readout for the expressionpattern of themutated genes.
3. Activating (Fig. 1D) – this transposon design activates nearby
genes from its promoter and splice donor. Additional sensitisingor cooperating transgenes can be added via an expression cas-
sette within the construct.
4. Gene expression (Fig. 1E) – this is a gene expression construct
using expression of transposase to mediate insertion into the
genome.
5. Promoter/enhancer trap (Fig. 1F) – this transposon design traps
transcripts from genes it lands in/near to, and expresses its pay-
load cDNA through an internal ribosomal entry sequence (IRES).
This assays the phenotype associated with a cDNA upon sto-
chastic and ectopic expression in vivo.
2.3. Transposon delivery into cells
1. 10 cm diameter tissue culture dishes (Corning 430167).
2. 96-well round bottom tissue culture plate (Corning 3790).
3. 24-well tissue culture plate (Corning 3524).
4. M15 medium – Knockout DMEM (GIBCO 10829018) + 15%
FBS (Invitrogen 10108165), 1 PSG (Penicillin, Streptomycin
and Glutamine, GIBCO 10378016), 1 Non-Essential Amino
Acids (GIBCO 11140035), 0.1 mM b-mercaptoethanol (Sigma
M6250), 1000 U/ml murine or human LIF (Millipore
ESG1107, LIF1010).
5. M10 medium – Knockout DMEM (GIBCO 10829018) + 10%
FBS (Invitrogen 10108165), 1 PSG (Penicillin, Streptomycin
and Glutamine, GIBCO 10378016), 1 Non-Essential Amino
Acids (GIBCO 11140035).
6. Dulbecco’s phosphate buffered saline (PBS, Invitrogen
14190169).
7. 0.05% Trypsin–EDTA (GIBCO 25300054).
8. Centrifuge (Eppendorf 5810).
9. Gene Pulser electroporation cuvette, 40 mm gap (Bio-Rad
165-2088).
10. Gene Pulser Xcell electroporation system (Bio-Rad 165-
2660).
11. Geneticin selective antibiotic liquid (Invitrogen 10131-027).
12. 0.1% (w/v) gelatin in sterile water, autoclaved (Sigma
G9136).
13. Mitotically inactive SNL76/7 feeder cells (cell line and its
associated protocols are available from Sanger Institute,
see above. Also available at ATCC/LGC standards, http://
www.lgcstandards-atcc.org/ or http://www.atcc.org).
14. Dimethyl Sulfoxide (DMSO, Sigma D2650).
15. MEF nucleofector kit 2 (Lonza VPD-1005).
16. Nucleofector Device (Lonza AAD-1001).2.4. Mapping insertion sites by splinkerette PCR
1. DNeasy blood and tissue kit (Qiagen 69506).
2. Sau3A I restriction enzyme (New England Biolabs, NEB
R0169L).
3. Thermal cycler (MJ Research PTC240).
4. Extensor Long PCR Master Mix, Buffer 1 (ABgene AB-0792/
A).
5. QIAquick PCR Puriﬁcation Kit (Qiagen 28106).
6. pGEM-T Easy Vector (Promega A1360).
7. Library Efﬁciency DH5 alpha Competent Cells (Invitrogen
18263012).
8. QIAprep Spin Miniprep Kit (Qiagen 27106).
3. Methodology
3.1. Transposon delivery into cells
For transposon delivery into mouse embryonic stem (ES) cells,
we use the following electroporation protocol. This basic protocol
is routinely adapted and optimised for other cell lines and delivery
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ciently deliver transgenes into the genome. Cells containing the
transgenes are selected for using a Neomycin resistance cassette
that is introduced either in the transgene constructs themselves
or by co-electroporation of a PB-SB-pGK-Neo construct. After trans-
gene delivery into mouse embryonic stem (ES) cells and genotyp-
ing for the desired clones, they can be made into mouse lines by
blastocyst injections.
1. A 10 cm dish of ES cells at approximately 80% conﬂuency is
fed 2–4 h before being trypsinized for electroporation.
2. For each electroporation, prepare plasmid DNA mix as fol-
lows, 2 lg of PL622 PB transposase plasmid and 20 lg of
transposon plasmid DNA.
3. Aspirate media from the 10 cm plate with ES cells, wash the
dish with 10 ml PBS, aspirate PBS, repeat wash.
4. Trypsinise cells by adding 2 ml 0.05% trypsin/EDTA, swirl to
cover entire surface. Place back in incubator for 15 min.
5. Add 2 ml M15 media and titurate to dissociate cells
thoroughly.
6. Pellet cells by centrifuging for 5 min at 200 RCF in a centri-
fuge (1000 rpm) and resuspend the cells in PBS to a density
of 1.1  107 cells/ml.
7. For each electroporation, pipette 900 ll of cell suspension
(107 cells) into the tubes from (Step 2) containing DNA.
8. Pipette the DNA/cell mixture into a Gene Pulser electropor-
ation cuvette, avoid touching the metal plates.
9. Electroporate the cells by placing the cuvette in the electro-
poration holder of the Bio-rad GenePulser. Set the machine
to 230 V, 500 lF, time constant is expected to be between
5.6 and 8.0.
10. Transfer the cells gently from the cuvettes into 9 ml M15.
Seed 1000 cells in a 10 cm dish with M15 media.
11. To select for cell clones containing the transgenes, replace
with M15 media supplemented with 125 lg/ml Geneticin
after 24 h. Colonies will be visible to the naked eye 7–
10 days later. The media would need to be replaced
daily.
12. To pick clones, aspirate media from the dish, wash the plate
with 10 ml PBS, aspirate PBS, replace with 7 ml PBS.
13. Pick the colony up from the plate using a 20 ll pipette set to
4 ll. Dispense the cell clump in 50 ll of 0.05% trypsin/EDTA
in a 96-well round bottomed plate. Incubate at 37 C for
10 min.
14. Add 50 ll M15 to each well and titurate to dissociate thor-
oughly. Seed cell suspension to a fresh 24-well plate with
M15 media.
15. Cell clones isolated can be used for further expansion, geno-
typing and subsequent injection into blastocysts to generate
animal lines by standard techniques.
For transposon delivery into mouse embryonic ﬁbroblasts
(MEF) cells, we use the following nucleofection protocol with the
MEF nucleofector kit 2. In this example, different combinations of
expression constructs are tested for their ability to reprogramme
MEFs into clonogenic induced pluripotent stem cells (iPSCs).
1. Preparation of SNL76/7 feeder cells (feeders should be
seeded in the culture dishes 1–3 days before use).
1.1 SNL76/7 cells are cultured in gelatinised tissue culture
dishes with M10 media. Prepare gelatinised plates by
coating 10 cm dishes with 0.1% gelatin solution for
30 min at room temperature. Aspirate before use.
1.2 When cells are conﬂuent, mitotically inactivate the cells
by treatment with 10 lg/ml mitomycin c M10 media for
2 h.1.3 Wash twice with PBS, aspirating completely between
washes. Cells can be used immediately or frozen down
in large batches in M10 + 10% DMSO.
1.4 Thaw a vial of mitotically inactive SNL76/7 cells in
10 ml M10 media.
1.5 Pellet cells by centrifuging for centrifuge 5 min at 200
RCF (1000 rpm). Aspirate and resuspend gently in M10
media.
1.6 Plate 4  106 cells in each 10 cm dish. Allow cells to
adhere at least overnight.
1.7 Before use, aspirate M10 media and replace with M15
media.
2. MEF cells are grown in M10 media. Cells in a 10 cm plate are
used when approximately 80% conﬂuent.
3. For each electroporation, prepare plasmid DNA mix as fol-
lows, 1 lg of PL622 PB transposase plasmid and 2 lg of
transposon plasmid DNA, and 100 ll of MEF II solution (from
the nucleofector kit).
4. Aspirate media from plate, wash plate with 10 ml PBS, aspi-
rate PBS.
5. Trypsinise cells by adding 4 ml 0.05% trypsin/EDTA, swirl to
cover entire surface. Place back in incubator for 5–10 min
until the cells lift off the plate.
6. Resuspend thoroughly by adding 4 ml M10 media and titur-
ate to dissociate thoroughly.
7. Count cell numbers using a haemocytometer and for
each nucleofection, centrifuge 106 cells for 5 min at
200 RCF.
8. Resuspend cells in DNA + MEF II solution, and pipette into
the kit cuvette.
9. Place cuvette into the Nucleofector device and use pro-
gramme A-023, press ‘X’ on the Nucleofector device to start
the programme.
10. Add 0.5 ml M15 media to the cuvette immediately and
transfer cells gently into 10 cm culture dish using the sterile
transfer pipette from the kit.
11. Colonies will be visible after 8–21 days. Colony numbers,
cellular morphology and other assays for assessing repro-
gramming quality are scored.
3.2. In vivo genetic screen for cancer genes
The general scheme for in vivo screening of cancer genes is to
combine either activating/inactivating/bi-functional transposons
with a source of transposase, the transposons will then translocate
and stochastically activate or inactivate genes in somatic cells.
Where these resultant mutation events are tumorigenic, the tu-
mours that arise would have either oncogenes activated or tumour
suppressor genes inactivated by the transposon, conferring a selec-
tive advantage to the clone. The cancer genes are identiﬁed by
mapping the insertion sites of the transposons in the tumour
genome to identify common insertion sites (CIS). Mouse lines
containing transposons are crossed to a transposase-containing
mouse line (Fig. 2). The progeny that contain both transposon
and transposase undergoes somatic insertional mutagenesis, these
comprise the experimental cohort for tumour watch. A screen to
identify cancer genes using a bi-functional activating/inactivating
transposon is described below.
1. ATP2 construct – ATP2 transposon is generated in pBlue-
Script as bi-functional transposons that contain splice
acceptors to trap surrounding transcripts and the MSCV
(murine stem cell virus long terminal repeat) promoter to
drive ectopic expression of nearby genes.
2. ATP2 mouse line – the ATP2 construct is used to generate
founder lines by pro-nuclear injections. Successful founder
Fig. 2. Typical genetic cross scheme for obtaining F1 experimental cohort mice
carrying both the PB transposons and the transposase. The PLPB Rosa-PBase line
used herein results in whole body somatic mobilisation of the transposons.
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the concatemer donor loci. Multiple ATP2 transgenic lines
are established F2 mice, each with single transposon donor
locus in the genome.
3. Generation of tumour watch animals – ATP2 lines are
crossed to the constitutive Rosa-PBase line to generate the
tumour watch cohort. The survival curves of these animals
are shown in Fig. 3. Only animals with both transposon
and transposase develop tumours with high penetrance,
but not animals with only the transposon or transposase.
4. Identiﬁcation of CIS and cancer genes – splinkerette PCR
(see Section 3.4) is used to identify the insertion sites of
transposons in tumours. The common insertion sites in
the genome that occur more than which would be expected
by chance are identiﬁed using previously described meth-
ods [22,23].
We have observed that both tumour spectrum and latency are
related to the design of the transposon construct, speciﬁcally the
kind of promoter used to drive ectopic expression of oncogenes
[20]. ATP2 lines generated highly penetrant haemopoietic malig-
nancies. In contrast, tumours driven by bi-functional transposon
with the CAGG promoter were predominantly solid, and those with
the PGK promoter were mixed.Fig. 3. Survival curves of multiple ATP2 lines. Mice with ATP2 transposons and
constitutive PB transposase expression show signiﬁcantly decreased survival.3.3. In vivo validation of human cancer mutations
We previously described using a promoter trap version of an SB
transposon that ectopically overexpresses promoterless cancer
gene cDNAs in vivo [24]. With a constitutive transposase expres-
sion in the mouse line, the promoter trap transposons sample mul-
tiple developmental and tissue contexts in the whole body to assay
the oncogenic potential of its cargo cDNA. Known human onco-
genes produced murine tumours that recapitulated the spectrum
observed in human patients. We have developed an updated de-
sign of the transposon (Fig. 1F) that requires less cloning steps
and allows pools of candidate cancer mutations to be validated
in vivo.
1. Enhancer trap constructs – candidate mutant cDNAs are
identiﬁed from human cancer genomes. Both the wildtype
and mutant cDNAs are generated and cloned into the
enhancer trap transposon vector (Fig. 1F), a unique
sequence tag 30 of the stop codon in each cDNA facilitates
ease of transgene genotyping and discriminating between
endogenous vs transgene expression.
2. Generation of ES cell clones with pooled transposons trans-
genes – transposon constructs are electroporated into ES
cells as a pool using the protocol in Section 3.1. The repre-
sentation of each construct in a clone is detected by PCR
using primers to the unique sequence tags. Activating trans-
position in animal lines with high transposon copy numbers
can result in embryonic lethality. Using pools of 25 transpo-
sons per electroporation, we have recovered ES cell clones
with up to 20 unique transposon insertions that give rise
to chimaeras capable of germline transmission.
3. ES cell clones with multiple unique transposon integrations
are injected into blastocysts to generate chimaeras using
standard techniques.
4. Generation of tumour watch animals – chimaera animals
are crossed to the constitutive Rosa-PBase line to generate
the tumour watch cohort. As the transposons are introduced
by pooled electroporation, the ES cell clones used to gener-
ate the chimaeras will have multiple insertion sites, the
results in segregation of the transposons in the F1 tumour
watch cohort. Each animal will have to be genotyped again
to determine the compliment of transposons it has inher-
ited. We have found highly variable latency and grades in
the tumours that develop, depending on the oncogenic
potential of the cDNA payload.
5. Recovery of tumorigenic mutant cDNAs – tumours that
develop are assessed for the presence of transposon and
for the expression of its cDNA payload. If an enhancer trap-
ping transposon expresses an oncogenic cDNA in a suitable
cell-type and developmental stage, it will drive the clonal
expansion of the tumorigenic clone. Splinkerette PCR (see
Section 3.4) is used to identify the insertion sites of transpo-
sons in tumours to establish clonal relationships between
multiple tumours in an animal.
We have observed that in some bulk tumours, there is loss of
multiple transposons compared to other normal tissues, and only
a few highly expressed transposons remain. It is likely that trans-
posons are lost through failure to re-integrate upon mobilisation
in the dividing tumour cells, the retention of select transposons
is indicative of purifying selection pressures to retain the driver
oncogene cDNAs. We have not observed control non-oncogenic
cDNAs expression at high levels in tumours, they are sometimes
observed to be expressed at low levels in normal tissues due to sto-
chastic enhancer trapping.
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To identify the insertion sites of the transposons in the genetic
screens, we use a PCR-based splinkerette strategy that has been
previously described [25]. A fragment of the transposon and adja-
cent genomic sequence is sequenced, allowing for mapping of the
insertion site. The protocol as follows clones the insertion sites for
sequencing. The number of colonies to be picked for sequencing
depends on the transposon copy number in the genome, with more
picked colonies allowing better recovery of the unique insertion
sites.











1. Extract genomic DNA from tissues or expanded cell clones
using DNeasy blood and tissue kit.
2. Digest 3 lg of genomic DNA with 4 U of Sau3A I in a reaction
volume of 40 ll at 37 C for 3 h, the enzyme is then deacti-
vated at 65 C for 20 min.
3. Generate the splinkerette adapter by annealing 150 pmol of
HMSpAa and HMSpBb oligos together in 0.5 NEB buffer 2,
ﬁnal volume of 100 ll. The oligonucleotides are denatured
at 65 C for 5 min, then cooled to room temperature at
1 C per 15 s using a thermal cycler. Annealed splinkerette
stock is aliquoted and stored at 20 C.
4. Ligate 750 ng (10 ll) of digested DNA to 4.5 pmols of
splinkerette (3 ll) using 400 U T4 ligase (NEB M0202L) in
ﬁnal volume of 20 ll, incubate at 16 C for 16 h, then inacti-
vate at 65 C for 10 min.
5. First round PCR is ampliﬁed with 5 ll of ligated DNA, 0.2 lM
HMSp1, 0.2 lM PB-L-Sp1 (for mapping 50 end of the trans-
poson, use PB-R-Sp1 if mapping the 30 end), 12.5 ll 2
PCR mix, ﬁnal volume of 25 ll. PCR conditions are 94 C
for 1 min 30 s; then two cycles of 94 C for 1 min, 68 C
for 1 min 30 s; then 30 cycles of 94 C for 30 s, 65 C for
30 s, 68 C for 2 min; then 68 C for 10 min.
6. Dilute the ﬁrst round PCR product 1:100 with sterile water.
7. The nested PCR is ampliﬁed with 5 ll diluted 1st round PCR
product, 0.2 lM HMSp2, 0.2 lM PB-L-Sp2 (for mapping 50
end of the transposon, use PB-R-Sp2 if mapping the 30
end), 12.5 ll 2 PCR master mix, ﬁnal volume of 25 ll.
PCR conditions are 94 C for 1 min 30 s; then 30 cycles of
94 C for 30, 60 C for 30 s, 68 C for 1 min 30 s; then 68 C
for 10 min.
8. Purify the nested PCR product using QIAquick puriﬁcation
kit. The puriﬁed product is ligated into the pGEM-T vector
and transformed into DH5-alpha E. coli cells as per kit
instructions. The resultant colonies are picked for minipreps
and sequenced by standard primers such as T7 and SP6.9. The sequencing results are analysed by aligning the ﬂanking
sequences to the genome to map the insertion sites of the
transposons.
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